LUCIUS 卢修斯 厄达替尼 Erdafitinib尿路上皮癌

厄达替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Erdafitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

LUCIUS

尿路上皮癌

iciErda is a kinase inhibitor indicated for the treatment
of sdult ostients with locally advanced or metastati

PHARMACEUTICALS

waleli carcinoma (mUCHthalhas
* susceptible FGFR3 or FOFR2 genetic alterations and
progressed dunng or Tollowing at least one line ot pr
plateun-cenlamng chemotherigy icliding wihon 12
months of neozdjavant or ad uvanf platinom-cortaunin

LuciErda

chemateragy
Denageand Use
Confirn the presence of FOFR genetic altertions

Erdafitinib Tablets

FDA批准

*Recommended imitil dosage 1mg orally once dail
with a dose increase to 9 mg dai lv if criteria are me
Swallow whole with or without food
Storages in a dry place and store at 20°C1o 25°C
Waring
Koeg medicine aut of reach of Chldron Do not udniniste
LociErda durine Precnases and Lactution
PLEASE SEEPACKAGEINSER

3mg

Mamfictured and Marketed b
LUCIUS

权威认证

Thongmang village. Xasthaoy district. Vientiane

28 Tablets

l regisered physicians only. and as directid
oy lhe paysician

Rx Only

口碑质量

适应症:
适用于治疗患有局部晚期或转移性尿路上皮癌的成年患者
推荐剂量:
起始剂量为8mg每日一次,空腹或随餐口服,在第14天和第21天
之间血磷水平低于5.5mg/dL目标值的患者,剂量增加至9mg每
日一次,直至疾病进展或无法耐受。
如果服药后发生呕吐,不可补服,下次服药仍按照原间隔时间。如
果漏服,当日内可以按量补服,下次服药仍按照原间隔时间。